BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 28687572)

  • 21. Personalising the treatment of prostate cancer.
    Gunjur A
    Lancet Oncol; 2015 Dec; 16(16):e592. PubMed ID: 26549591
    [No Abstract]   [Full Text] [Related]  

  • 22. Session 2: Mutational discordance: the big challenge in personalized treatments - any solutions?
    Siddiqui M; Chand M; Eng C; Mehdizadeh A; Mirnezami A; Brown G
    Colorectal Dis; 2018 May; 20 Suppl 1():49-51. PubMed ID: 29878676
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The forest and the trees: pathways and proteins as colorectal cancer biomarkers.
    Bertagnolli MM
    J Clin Oncol; 2009 Dec; 27(35):5866-7. PubMed ID: 19884524
    [No Abstract]   [Full Text] [Related]  

  • 24. Next-Generation Sequencing in Oncology in the Era of Precision Medicine.
    Blumenthal GM; Mansfield E; Pazdur R
    JAMA Oncol; 2016 Jan; 2(1):13-4. PubMed ID: 26540172
    [No Abstract]   [Full Text] [Related]  

  • 25. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
    Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
    Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biomarker-Driven Treatments Yield Better Results.
    Cancer Discov; 2016 Aug; 6(8):OF4. PubMed ID: 27357459
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paul Workman: Drugging the Cancer Genome.
    Trends Cancer; 2016 Oct; 2(10):544-548. PubMed ID: 27904887
    [No Abstract]   [Full Text] [Related]  

  • 28. Adaptive clinical trial designs for simultaneous testing of matched diagnostics and therapeutics.
    Scher HI; Nasso SF; Rubin EH; Simon R
    Clin Cancer Res; 2011 Nov; 17(21):6634-40. PubMed ID: 22046024
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneity.
    Gandara DR; Li T; Lara PN; Mack PC; Kelly K; Miyamoto S; Goodwin N; Beckett L; Redman MW
    Clin Lung Cancer; 2012 Sep; 13(5):321-5. PubMed ID: 22677432
    [No Abstract]   [Full Text] [Related]  

  • 30. Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?
    Weller M; Wick W; Hegi ME; Stupp R; Tabatabai G
    Future Oncol; 2010 Sep; 6(9):1407-14. PubMed ID: 20919826
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Precision medicine: A major step forward in specific situations, a myth in refractory cancers?].
    Albin N; Mc Leer A; Sakhri L
    Bull Cancer; 2018 Apr; 105(4):375-396. PubMed ID: 29501208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Editorial comment.
    Lotan Y; Merseburger AS
    Curr Opin Urol; 2017 Jan; 27(1):34. PubMed ID: 27902674
    [No Abstract]   [Full Text] [Related]  

  • 33. Probabilistic medicine: a pre-emptive approach is needed for cancer therapeutic risk mitigation.
    Hicks JK; McLeod HL
    Biomark Med; 2019 Aug; 13(12):987-990. PubMed ID: 31385527
    [No Abstract]   [Full Text] [Related]  

  • 34. Next generation sequencing for gynecologic malignancy: Promise and potential pitfalls.
    Hinchcliff EM; Westin SN
    Gynecol Oncol; 2021 Nov; 163(2):217-219. PubMed ID: 34756289
    [No Abstract]   [Full Text] [Related]  

  • 35. Precision medicine in pediatric oncology.
    Forrest SJ; Geoerger B; Janeway KA
    Curr Opin Pediatr; 2018 Feb; 30(1):17-24. PubMed ID: 29189430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The evolving potential of companion diagnostics.
    Khoury JD
    Scand J Clin Lab Invest Suppl; 2016; 245():S22-5. PubMed ID: 27433788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular selection trumps clinical selection.
    Shepherd FA
    J Clin Oncol; 2011 Jul; 29(21):2843-4. PubMed ID: 21670452
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment strategy for metastatic breast cancer according to intrinsic subtype.
    Noguchi S
    Int J Clin Oncol; 2010 Aug; 15(4):333-4. PubMed ID: 20632058
    [No Abstract]   [Full Text] [Related]  

  • 39. Recent updates of precision therapy for gastric cancer: Towards optimal tailored management.
    Joo MK; Park JJ; Chun HJ
    World J Gastroenterol; 2016 May; 22(19):4638-50. PubMed ID: 27217696
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lack of access to targeted cancer therapy.
    Burki TK
    Lancet Oncol; 2015 Oct; 16(13):e482. PubMed ID: 26321211
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.